Difference between revisions of "Globalisation:National Obesity Forum"
Emma Patrick (talk | contribs) (→Views on tackling obesity) |
Emma Patrick (talk | contribs) (→Conflicts of Interest) |
||
| Line 52: | Line 52: | ||
===Conflicts of Interest=== | ===Conflicts of Interest=== | ||
| + | |||
| + | Sanofi-Aventis LTD is one of the NOF’s sponsors, yet the anti-obesity medication that they produced was proven to be unsafe and the drugs were withdrawn following a series of reported serious side-affects. Rimonabant (Acompila) was prescribed to ninety seven thousand people in the UK. Its circulation was suspended in October 2008, after only four months on the market, as it was found to be dangerous to many of those who took it. It was found that between June and August 2008, five of those who were taking the drug committed suicide, and many others experienced psychiatric problems. The risk of such problems, especially depression, was increased when the patient had a history of mental health problems. <ref> BBC "[http://news.bbc.co.uk/1/hi/health/7687311.stm]" accessed 2 November 2010 </ref> | ||
| + | Dr Colin Waine, who was chairman of the NOF at the time, was disapointed that the drug had to be withdrawn as he found that many of his patients were doing well on it and had experienced no problems, and did not appear to be concerned about the drug. | ||
==NOF Conference== | ==NOF Conference== | ||
Revision as of 15:58, 2 November 2010
Emma Patrick Christina McDonald Rachel Cunningham
http://www.nationalobesityforum.org.uk/
Contents
History
The National Obesity Forum was created in 2000 by a group of health professionals and is a registered charity (1109600).
The main aims of the NOF are to:
-Increase the public focus on obesity and develop more awareness about the health implications.
-To help educate more people on the topic of obesity and health from an earlier age.
-To encourage the Government to make tackling obesity a priority, in order to save the NHS money in future years.
People
Views on tackling obesity
The National Obesity Forum advocate many ways of tackling obesity.
-They advise increasing activity levels, and put importance on making exercise ‘fun’ and easy by focussing on ordinary activities such as gardening, shopping, and sports.
-They also advise making a personal plan to suit each individual.
-They provide information on how to have a healthy diet and put importance on portion control.
- Advice is also given on 'positive thinking' and how this can impact a person's ability to lose weight.
The NOF also back more drastic and often risky means of weight loss, including; very low calorie diets, medication, meal replacements, and even surgery.
With regards to weight loss medication (or 'Anti-Obesity Medication), the NOF mention two specific drugs - Sibutramine(Reductil) and Orlistat(Alli).
One of these drugs - Orlistat - was actually the first 'over the counter' weight loss drug available, and was produced by Glaxosmithkline, which is one of the NOFs parter organisations. [1]
The NOF is highly funded by pharmaceutical companies, however, there have been disputes regarding whether weight loss medication actually works. Former President of the NOF, Dr Ian Campbell, resigned from his post after stating that the forum places too much importance on weight loss drugs, and not enough on putting measures in place to prevent obesity in the first place. Dr Campbell claimed that the forum had changed direction and did not have the same outlook as it did when it began.
[2]
Conflicts of Interest
Sanofi-Aventis LTD is one of the NOF’s sponsors, yet the anti-obesity medication that they produced was proven to be unsafe and the drugs were withdrawn following a series of reported serious side-affects. Rimonabant (Acompila) was prescribed to ninety seven thousand people in the UK. Its circulation was suspended in October 2008, after only four months on the market, as it was found to be dangerous to many of those who took it. It was found that between June and August 2008, five of those who were taking the drug committed suicide, and many others experienced psychiatric problems. The risk of such problems, especially depression, was increased when the patient had a history of mental health problems. [3] Dr Colin Waine, who was chairman of the NOF at the time, was disapointed that the drug had to be withdrawn as he found that many of his patients were doing well on it and had experienced no problems, and did not appear to be concerned about the drug.
